# Biotechnology Value Fund

> Biotechnology Value Fund is a VC fund backing Biotechnology and Health Care. See 169 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 169
- Last investment: Jul 2026
- Lead investor: 28%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/bvf-partners-l.p
- Website: http://www.bvflp.com

Biotechnology Value Fund is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments.Since its inception in 1993, BVF has strived to build concentrated, long-term investments in small-cap biotechnology companies while performing rigorous diligence and on-going monitoring of itsinvestments.BVF is committed to working with its portfolio companies as partners in their successes.

## Contacts

5 contacts available for Biotechnology Value Fund. Shizune tracks 8 team members at Biotechnology Value Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/biotechnology-value-fund?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $8.9M–$177M |
| Series B | $40M–$140M |
| Post-IPO Equity | $20M–$200M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 112 | 66% |
| Health Care | 65 | 38% |
| Therapeutics | 57 | 34% |
| Pharmaceutical | 42 | 25% |
| Medical | 36 | 21% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 55 | 33% |
| Series B | 41 | 24% |
| Series A | 24 | 14% |
| Series C | 13 | 8% |
| Venture - Series Unknown | 4 | 2% |

13 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 96 | 57% |
| Switzerland | 5 | 3% |
| Canada | 3 | 2% |
| Israel | 3 | 2% |
| United Kingdom | 2 | 1% |

9 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gorjan Hrustanovic | Managing Director | 8 | https://shizune.co/investors/profile/gorjan-hrustanovic |
| James Kratky | Chief Financial Officer, Chief Compliance Officer | 0 | https://shizune.co/investors/profile/james-kratky-fa8b |
| Matthew Perry | Portfolio Manager | 0 | https://shizune.co/investors/profile/matthew-perry |
| Michael Murray | Managing Director | 0 | https://shizune.co/investors/profile/michael-murray-7 |
| Sam Huang | Principal | 1 | https://shizune.co/investors/profile/sam-huang |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Entera Bio | Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience andnetworks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience. | $275M | Post-IPO Equity | Jul 27, 2026 |  |
| Contraline | Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible. | $92.5M | Series B | Jun 02, 2026 |  |
| Q32 Bio | Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $55M | Post-IPO Equity | May 26, 2026 |  |
| Sagimet Biosciences | Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASNinhibitors. | $175M | Post-IPO Equity | Apr 27, 2026 |  |
| Entera Bio | Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience andnetworks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience. | $10M | Post-IPO Equity | Apr 02, 2026 |  |
| Ambrosia Biosciences | Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders. | $100M | Series B | Mar 31, 2026 |  |
| OnKure Therapeutics | OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solidtumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized. | $150M | Post-IPO Equity | Mar 27, 2026 |  |
| Immunic Therapeutics | Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolismof activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. | $400M | Post-IPO Equity | Feb 13, 2026 |  |
| Sutro Biopharma | Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF.Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. | $110M | Post-IPO Equity | Feb 10, 2026 |  |
| Third Arc Bio | Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases. Its drug development engine delivers superior biologics optimized to create T-cell engagement by leveraging two technologies that power a pipeline of high-value therapeutics – a solid tumor synergy platform and an I&I platformthat offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. | $52M | Series A | Feb 04, 2026 |  |

10 of 169 investments shown.

## Co-investors
- [Biotechnology Value Fund](https://shizune.co/investors/profile/bvf-partners) — VC Fund, 102 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/bvf-partners-3e10) — VC Fund, 97 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 49 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 38 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 29 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 26 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Life Science Investors](https://shizune.co/investors/life-science-investors)
- [Life Science VC Funds](https://shizune.co/investors/life-science-vc-funds)
- [Life Science Investors in United States](https://shizune.co/investors/life-science-investors-united-states)
- [Life Science VC Funds in United States](https://shizune.co/investors/life-science-vc-funds-united-states)

## FAQ

### What does Biotechnology Value Fund invest in?

Biotechnology Value Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 169 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Biotechnology Value Fund's check size?

Biotechnology Value Fund typically joins rounds of $8.9M–$177M at Series A, $40M–$140M at Series B and $20M–$200M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Biotechnology Value Fund participates in.

### How do I contact Biotechnology Value Fund?

Public channels for Biotechnology Value Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Biotechnology Value Fund?

The team at Biotechnology Value Fund includes Gorjan Hrustanovic (Managing Director), James Kratky (Chief Financial Officer, Chief Compliance Officer) and Matthew Perry (Portfolio Manager), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co